Pacific Edge Ltd

Pacific Edge operates with a current ratio of 3.16, indicating strong short-term liquidity, supported by NZD 9.48 million in cash and equivalents against NZD 10.95 million in total liabilities. However, the company’s negative operating cash flow of NZD -24.74 million and free cash flow of NZD -28.39 million suggest ongoing operational strain, with capital expenditures of NZD -1.27 million further pressuring liquidity. Profitability metrics are sharply negative, with a return on equity of -114.76% and return on assets of -80.84%, far below the industry median for diagnostics firms, which typically report positive ROE and ROA in the 5-15% range. The company’s operating and net losses of NZD -31.77 million and NZD -29.94 million, respectively, underscore its unprofitable operations and reliance on equity and cash reserves to sustain operations. The company’s revenue is concentrated across two segments: Commercial and Research. The Commercial segment drives sales and lab operations, while the Research segment focuses on R&D for diagnostic products. Geographic exposure is limited to New Zealand, Australia, Singapore, and the U.S., with no disclosed revenue concentration by region. Growth remains uncertain, with no forward-looking revenue guidance provided. Analysts have assigned a mean price target of NZD 0.12, with a median of NZD 0.12 and a high of NZD 0.16, reflecting limited upside potential. The company’s negative operating cash flow and lack of profitability suggest a challenging path to growth, absent significant R&D breakthroughs or strategic partnerships. Risk factors include liquidity constraints, with a low liquidity rating and negative cash flows, and unassessed dilution risk due to missing share count data. The absence of strong buy or buy analyst ratings further highlights the company’s speculative profile. Recent events include the continued commercialization of Cxbladder tests and ongoing R&D efforts, though no material filings or transcripts have been disclosed to indicate strategic shifts or regulatory progress.